EUVIMEDEUVIMED entdecken
Crossref

Echinocystic acid prevents obesity and fatty liver via interacting with FABP1

Lianggui Xiao, Mingming Li, Yang Xiao, Lin Yu, Yu Li, Zhiwang Zhang, Guo Zhang, Yixing Li iD, Lei Zhou iD, Yunxiao Liang

Phytotherapy Research · 2023-08 · 37 (8) · 3617-3630

DOI: 10.1002/ptr.7839 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytotherapy Research, online erschienen am 24.04.2023. Verfasst von Lianggui Xiao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China. Hauptthemen laut MEDLINE: Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Guangxi Digestive Disease Clinical Medical Research Center Construction Project, Guangxi Health Commission Key Laboratory of Portal Hypertension Prevention and Control Research, Guangxi Science Foundation for Distinguished Young Scholars.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long‐term high‐fat diet (HFD) will lead to obesity and their complications. Echinocystic acid (EA), a triterpene, shows anti‐inflammatory and antioxidant effects. We predict that EA supplementation can prevent obesity, diabetes, and nonalcoholic steatohepatitis. To test our hypothesis, we investigated the effects of EA supplementation on mice with HFD‐induced obesity in vivo and in vitro by adding EA to the diet of mice and the medium of HepG2 cells, the protein target of EA was analyzed by molecular docking. The results showed that EA ameliorated obesity and inhibited blood triglyceride and liver triglyceride concentrations than those in the HFD groups. The data on molecular docking indicated that FABP1 was a potential target of EA. Further experimental results confirmed that EA affected the triglyceride level by regulating the function of FABP1. This study may provide a new potential inhibitor for FABP1 and a new strategy for the treatment of obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiverNon-alcoholic Fatty Liver DiseaseAnimalsMiceMolecular Docking SimulationObesityTriglyceridesDiet, High-FatMice, Inbred C57BLLipid MetabolismOleanolic Acid

Stichwörter der Autor:innen

FABP1NAFLDechinocystic acidglucoselipid metabolismobesity

Substanzen

Triglyceridesechinocystic acidOleanolic Acid

Autor:innen und Institutionen

  • Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
  • College of Animal Science and Technology, Guangxi University, Nanning, China.

ORCID-Profile: Yixing Li, Lei Zhou

Förderung

  • Guangxi Digestive Disease Clinical Medical Research Center Construction Project
  • Guangxi Health Commission Key Laboratory of Portal Hypertension Prevention and Control Research
  • Guangxi Science Foundation for Distinguished Young Scholars
  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangxi Province

Zitieren

APA

Xiao, L., Li, M., Xiao, Y., Yu, L., Li, Y., Zhang, Z., Zhang, G., Li, Y., Zhou, L., & Liang, Y. (2023). Echinocystic acid prevents obesity and fatty liver via interacting with FABP1. Phytotherapy Research, 37(8), 3617-3630. https://doi.org/10.1002/ptr.7839

Vancouver

Xiao L, Li M, Xiao Y, Yu L, Li Y, Zhang Z, et al. Echinocystic acid prevents obesity and fatty liver via interacting with FABP1. Phytotherapy Research. 2023;37(8):3617-3630. doi:10.1002/ptr.7839

BibTeX
@article{Xiao2023,
  author = {Xiao, Lianggui and Li, Mingming and Xiao, Yang and Yu, Lin and Li, Yu and Zhang, Zhiwang and Zhang, Guo and Li, Yixing and Zhou, Lei and Liang, Yunxiao},
  title = {Echinocystic acid prevents obesity and fatty liver via interacting with FABP1},
  journal = {Phytotherapy Research},
  year = {2023},
  volume = {37},
  number = {8},
  pages = {3617--3630},
  doi = {10.1002/ptr.7839}
}
Kostenlos starten →